Screen Shot 2016-11-07 at 10.01.56 PM.png

Qamelostat in clinical development

Based on findings in synthetic lethals screens The Netherlands Cancer Institute has initiated a trial testing Qamelostat (suberoylanilide hydroxamic acid) in BRAF resistant, BRAF mutant advanced melanoma

Trial details

Trial will run only in the Netherlands and is has as primary outcome measure anti-tumor response rate in at least 30% of the treated patients. Time Frame: CT scan every 6 weeks up to 24 months and monthly phone call until start of subsequent anticancer therapy or until all patients have been followed up for at least 24 months or have been lost to follow up, whichever occurs first.